-
1
-
-
39049174296
-
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder
-
Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67:e12.
-
(2006)
J Clin Psychiatry
, vol.67
-
-
Green, M.F.1
-
2
-
-
34447546649
-
A 12-week, double-blind, placebo- controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
-
Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo- controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 2007;21:421-427.
-
(2007)
J Psychopharmacol
, vol.21
, pp. 421-427
-
-
Lee, B.J.1
Lee, J.G.2
Kim, Y.H.3
-
3
-
-
33846986313
-
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia
-
Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007;22:63-68.
-
(2007)
Int Clin Psychopharmacol
, vol.22
, pp. 63-68
-
-
Lee, S.W.1
Lee, J.G.2
Lee, B.J.3
Kim, Y.H.4
-
4
-
-
84863429650
-
Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: A placebo-controlled pilot study
-
Lee JG, Lee SW, Lee BJ, Park SW, Kim GM, Kim YH. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012;9:166-173.
-
(2012)
Psychiatry Investig
, vol.9
, pp. 166-173
-
-
Lee, J.G.1
Lee, S.W.2
Lee, B.J.3
Park, S.W.4
Kim, G.M.5
Kim, Y.H.6
-
5
-
-
84855866544
-
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial
-
Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012;37:660-668.
-
(2012)
Neuropsychopharmacology
, vol.37
, pp. 660-668
-
-
Shim, J.C.1
Jung, D.U.2
Jung, S.S.3
Seo, Y.S.4
Cho, D.M.5
Lee, J.H.6
-
6
-
-
0036268294
-
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
-
DOI 10.1176/appi.ajp.159.6.1018
-
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028. (Pubitemid 34586949)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.6
, pp. 1018-1028
-
-
Bilder, R.M.1
Goldman, R.S.2
Volavka, J.3
Czobor, P.4
Hoptman, M.5
Sheitman, B.6
Lindenmayer, J.-P.7
Citrome, L.8
McEvoy, J.9
Kunz, M.10
Chakos, M.11
Cooper, T.B.12
Horowitz, T.L.13
Lieberman, J.A.14
-
7
-
-
21244448316
-
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
-
DOI 10.1017/S146114570500516X
-
Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-472. (Pubitemid 41002500)
-
(2005)
International Journal of Neuropsychopharmacology
, vol.8
, Issue.3
, pp. 457-472
-
-
Woodward, N.D.1
Purdon, S.E.2
Meltzer, H.Y.3
Zald, D.H.4
-
8
-
-
39649124515
-
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives
-
DOI 10.1097/jcp.0b013e31815ac4e5, PII 0000471420071200000013
-
Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27:639-661. (Pubitemid 351339452)
-
(2007)
Journal of Clinical Psychopharmacology
, vol.27
, Issue.6
, pp. 639-661
-
-
Byerly, M.1
Suppes, T.2
Tran, Q.-V.3
Baker, R.A.4
-
10
-
-
0036089687
-
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
-
DOI 10.1124/jpet.102.033175
-
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389. (Pubitemid 34680462)
-
(2002)
Journal of Pharmacology and Experimental Therapeutics
, vol.302
, Issue.1
, pp. 381-389
-
-
Burris, K.D.1
Molski, T.F.2
Xu, C.3
Ryan, E.4
Tottori, K.5
Kikuchi, T.6
Yocca, F.D.7
Molinoff, P.B.8
-
11
-
-
53549119665
-
Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors
-
Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol 2008;597:27-33.
-
(2008)
Eur J Pharmacol
, vol.597
, pp. 27-33
-
-
Tadori, Y.1
Forbes, R.A.2
McQuade, R.D.3
Kikuchi, T.4
-
12
-
-
0037177358
-
1A receptor
-
DOI 10.1016/S0014-2999(02)01532-7, PII S0014299902015327
-
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441:137-140. (Pubitemid 34626163)
-
(2002)
European Journal of Pharmacology
, vol.441
, Issue.3
, pp. 137-140
-
-
Jordan, S.1
Koprivica, V.2
Chen, R.3
Tottori, K.4
Kikuchi, T.5
Altar C.Anthony6
-
13
-
-
6044224986
-
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile
-
DOI 10.1177/026988110401800308
-
Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-383. (Pubitemid 39382565)
-
(2004)
Journal of Psychopharmacology
, vol.18
, Issue.3
, pp. 375-383
-
-
Hirose, T.1
Uwahodo, Y.2
Yamada, S.3
Miwa, T.4
Kikuchi, T.5
Kitagawa, H.6
Burris, K.D.7
Altar, C.A.8
Nabeshima, T.9
-
14
-
-
0346096591
-
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function
-
DOI 10.1016/j.ejphar.2003.10.025
-
Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53. (Pubitemid 38056603)
-
(2004)
European Journal of Pharmacology
, vol.483
, Issue.1
, pp. 45-53
-
-
Jordan, S.1
Koprivica, V.2
Dunn, R.3
Tottori, K.4
Kikuchi, T.5
Altar, C.A.6
-
15
-
-
58449126907
-
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study
-
APLUS Study Group
-
Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ; APLUS Study Group. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009;63:73-81.
-
(2009)
Psychiatry Clin Neurosci
, vol.63
, pp. 73-81
-
-
Kwon, J.S.1
Jang, J.H.2
Kang, D.H.3
Yoo, S.Y.4
Kim, Y.K.5
Cho, S.J.6
-
16
-
-
2942551105
-
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain
-
DOI 10.1016/j.ejphar.2004.04.028, PII S0014299904004133
-
Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493:75-83. (Pubitemid 38746934)
-
(2004)
European Journal of Pharmacology
, vol.493
, Issue.1-3
, pp. 75-83
-
-
Li, Z.1
Ichikawa, J.2
Dai, J.3
Meltzer, H.Y.4
-
18
-
-
70349811302
-
Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia
-
Kim SW, Shin IS, Kim JM, Lee JH, Lee YH, Yang SJ, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009;32:243-249.
-
(2009)
Clin Neuropharmacol
, vol.32
, pp. 243-249
-
-
Kim, S.W.1
Shin, I.S.2
Kim, J.M.3
Lee, J.H.4
Lee, Y.H.5
Yang, S.J.6
-
19
-
-
77949891795
-
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia
-
Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010;43:50-57.
-
(2010)
Pharmacopsychiatry
, vol.43
, pp. 50-57
-
-
Riedel, M.1
Spellmann, I.2
Schennach-Wolff, R.3
Musil, R.4
Dehning, S.5
Cerovecki, A.6
-
20
-
-
77749252648
-
Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone
-
Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2010;25:116-125.
-
(2010)
Hum Psychopharmacol
, vol.25
, pp. 116-125
-
-
Riedel, M.1
Schennach-Wolff, R.2
Musil, R.3
Dehning, S.4
Cerovecki, A.5
Opgen-Rhein, M.6
-
21
-
-
78650960469
-
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia
-
Suzuki H, Gen K, Inoue Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:161-168.
-
(2011)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.35
, pp. 161-168
-
-
Suzuki, H.1
Gen, K.2
Inoue, Y.3
-
22
-
-
72849140996
-
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
-
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348-1357.
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 1348-1357
-
-
Kane, J.M.1
Correll, C.U.2
Goff, D.C.3
Kirkpatrick, B.4
Marder, S.R.5
Vester-Blokland, E.6
-
23
-
-
84862137385
-
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients
-
Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 2012;26:806-812.
-
(2012)
J Psychopharmacol
, vol.26
, pp. 806-812
-
-
Yasui-Furukori, N.1
Kaneda, A.2
Sugawara, N.3
Tomita, T.4
Kaneko, S.5
-
24
-
-
34548307179
-
The diagnostic and statistical manual of mental disorders, fourth edition, text revision as an appropriate diagnostic for premature ejaculation
-
DOI 10.1111/j.1743-6109.2007.00557.x
-
Shabsigh R, Rowland D. The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision as an appropriate diagnostic for premature ejaculation. J Sex Med 2007;4:1468-1478. (Pubitemid 47337696)
-
(2007)
Journal of Sexual Medicine
, vol.4
, Issue.5
, pp. 1468-1478
-
-
Shabsigh, R.1
Rowland, D.2
-
25
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. (Pubitemid 18039085)
-
(1987)
Schizophrenia Bulletin
, vol.13
, Issue.2
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
26
-
-
20444376911
-
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
-
DOI 10.1016/j.schres.2005.02.013, PII S0920996405000782
-
Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265. (Pubitemid 40804771)
-
(2005)
Schizophrenia Research
, vol.76
, Issue.2-3
, pp. 247-265
-
-
Chouinard, G.1
Margolese, H.C.2
-
27
-
-
34648833682
-
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial
-
DOI 10.1176/appi.ajp.2007.06071075
-
Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-1410. (Pubitemid 47461141)
-
(2007)
American Journal of Psychiatry
, vol.164
, Issue.9
, pp. 1404-1410
-
-
Shim, J.-C.1
Shin, J.-G.K.2
Kelly, D.L.3
Jung, D.-U.4
Seo, Y.-S.5
Liu, K.-H.6
Shon, J.-H.7
Conley, R.R.8
-
28
-
-
58249085773
-
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study
-
Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009;107:218-222.
-
(2009)
Schizophr Res
, vol.107
, pp. 218-222
-
-
Byerly, M.J.1
Marcus, R.N.2
Tran, Q.V.3
Eudicone, J.M.4
Whitehead, R.5
Baker, R.A.6
-
29
-
-
78649506539
-
Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics
-
Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1495-1499.
-
(2010)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.34
, pp. 1495-1499
-
-
Chen, C.K.1
Huang, Y.S.2
Ree, S.C.3
Hsiao, C.C.4
-
30
-
-
77957252761
-
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia
-
Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010;30:596-599.
-
(2010)
J Clin Psychopharmacol
, vol.30
, pp. 596-599
-
-
Yasui-Furukori, N.1
Furukori, H.2
Sugawara, N.3
Fujii, A.4
Kaneko, S.5
-
31
-
-
68949212290
-
Aripiprazole: Dose-response relationship in schizophrenia and schizoaffective disorder
-
Mace S, Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009;23:773-780.
-
(2009)
CNS Drugs
, vol.23
, pp. 773-780
-
-
Mace, S.1
Taylor, D.2
-
32
-
-
77954354233
-
The staging model in schizophrenia, and its clinical implications
-
Agius M, Goh C, Ulhaq S, McGorry P. The staging model in schizophrenia, and its clinical implications. Psychiatr Danub 2010;22:211-220.
-
(2010)
Psychiatr Danub
, vol.22
, pp. 211-220
-
-
Agius, M.1
Goh, C.2
Ulhaq, S.3
McGorry, P.4
-
33
-
-
79952815943
-
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
-
Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011;41:225-241.
-
(2011)
Psychol Med
, vol.41
, pp. 225-241
-
-
Lewandowski, K.E.1
Cohen, B.M.2
Ongur, D.3
-
34
-
-
84857235422
-
Hierarchical structure of the cognitive processes in schizophrenia: The fundamental role of processing speed
-
Ojeda N, Peña J, Schretlen DJ, Sánchez P, Aretouli E, Elizagárate E, et al. Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophr Res 2012;135:72-78.
-
(2012)
Schizophr Res
, vol.135
, pp. 72-78
-
-
Ojeda, N.1
Peña, J.2
Schretlen, D.J.3
Sánchez, P.4
Aretouli, E.5
Elizagárate, E.6
-
35
-
-
47749140753
-
Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions
-
DOI 10.2174/138920008784746373
-
Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-418. (Pubitemid 352025195)
-
(2008)
Current Drug Metabolism
, vol.9
, Issue.5
, pp. 410-418
-
-
Urichuk, L.1
Prior, T.I.2
Dursun, S.3
Baker, G.4
|